# Allergic Rhinitis - Pathophysiology and Treatment

## Epidemiology and Classification

Allergic rhinitis is one of the most prevalent chronic diseases worldwide, affecting an estimated 10 to 30 percent of adults and up to 40 percent of children globally. Its impact extends far beyond nasal symptoms, significantly impairing quality of life, sleep quality, academic performance, and workplace productivity. In the United States alone, direct costs attributable to allergic rhinitis are estimated at approximately 3.4 billion dollars annually, underscoring the enormous public health burden of this condition.

The Allergic Rhinitis and its Impact on Asthma (ARIA) classification system has largely replaced the traditional seasonal versus perennial designation, providing a more clinically useful framework. ARIA categorizes allergic rhinitis along two axes. The first axis addresses duration, distinguishing intermittent disease (symptoms present fewer than four days per week or fewer than four consecutive weeks) from persistent disease. The second axis addresses severity, separating mild disease (in which sleep, daily activities, work, and school are not impaired) from moderate-severe disease (in which at least one of these domains is affected). This classification directly informs therapeutic decision-making.

Seasonal allergens include tree pollens predominating in spring, grass pollens in late spring and summer, ragweed in fall, and mold spores with variable seasonality depending on geographic location and climate. Perennial allergens encompass house dust mites (principally Dermatophagoides pteronyssinus and Dermatophagoides farinae), cat and dog dander, cockroach allergens, and indoor molds such as Alternaria and Aspergillus species. There is a strong association between allergic rhinitis and asthma, encapsulated in the united airway concept, which recognizes the upper and lower airways as a continuous functional unit sharing inflammatory pathways. Approximately 20 to 50 percent of patients with allergic rhinitis have comorbid asthma, while as many as 80 percent of asthmatic patients carry a concurrent diagnosis of allergic rhinitis.

## Pathophysiology

### Sensitization and Early Phase

The pathophysiology of allergic rhinitis begins with sensitization, during which allergens penetrate the nasal epithelium and are captured by dendritic cells of the Langerhans cell type residing in the nasal mucosa. Disruption of the epithelial barrier facilitates allergen uptake and simultaneously triggers release of epithelial alarmins, including thymic stromal lymphopoietin (TSLP), interleukin-25, and interleukin-33, which promote dendritic cell maturation and polarization of naive T cells toward a T helper 2 (Th2) phenotype. These Th2 cells produce interleukin-4 and interleukin-13, which drive B cell immunoglobulin class switching to IgE. The allergen-specific IgE then binds to high-affinity IgE receptors (FcepsilonRI) on the surface of mast cells residing in the nasal submucosa, arming them for subsequent responses.

Upon re-exposure to the sensitizing allergen, multivalent allergen molecules crosslink IgE antibodies on mast cell surfaces within minutes, triggering degranulation. Histamine, the principal preformed mediator, acts on H1 receptors on sensory nerve endings and nasal vasculature to produce the hallmark symptoms of sneezing, rhinorrhea, and nasal pruritus. Additional mediators released during the early phase include prostaglandin D2, leukotriene C4 and D4, kinins, and platelet-activating factor, each contributing to the inflammatory milieu.

### Late Phase Response

The late phase response develops approximately 4 to 8 hours after allergen exposure and is characterized clinically by nasal congestion that predominates over the sneezing and rhinorrhea of the early phase. This response is driven by recruitment and infiltration of eosinophils (in an interleukin-5-dependent manner), basophils, and Th2 lymphocytes into the nasal mucosa. Upregulation of adhesion molecules, particularly ICAM-1 and VCAM-1, on the vascular endothelium facilitates leukocyte recruitment from the circulation. Interleukin-13 induces goblet cell hyperplasia and mucus hypersecretion, contributing to the sensation of postnasal drip and nasal obstruction. With chronic, sustained inflammation, tissue remodeling ensues, manifesting as basement membrane thickening and subepithelial fibrosis, which may contribute to the persistence of symptoms even after allergen avoidance.

### Priming Effect

A clinically important phenomenon in allergic rhinitis is the priming effect, in which repeated allergen exposure progressively lowers the threshold required for mast cell activation. This occurs through increased expression of FcepsilonRI on mast cell surfaces and enhanced mediator release with each successive exposure. The clinical correlate of priming is familiar to many patients: symptoms worsen as the pollen season progresses, even though ambient allergen levels may remain relatively constant. Additionally, during periods of active allergic inflammation, patients frequently develop nonspecific hyperreactivity to irritants such as cigarette smoke, strong odors, and cold air, reflecting the heightened sensitivity of the inflamed nasal mucosa.

<image>A cross-sectional anatomy illustration of the nasal mucosa during allergic rhinitis, comparing a normal nasal mucosa (left) to an inflamed mucosa (right). The normal side shows intact epithelium with scattered goblet cells, submucosal glands, blood vessels, and rare mast cells. The inflamed side shows: edematous epithelium with disrupted tight junctions, increased goblet cells with mucus hypersecretion, IgE-armed mast cells degranulating in submucosa, dilated blood vessels with plasma extravasation, eosinophil infiltration with MBP granule release, Th2 cells releasing IL-4/IL-5/IL-13, sensory nerve endings with histamine-induced activation (sneezing reflex arc to CNS), and basement membrane thickening. Labels for each mediator and its clinical effect: histamine (sneezing, rhinorrhea, pruritus), leukotrienes (congestion), PGD2 (vasodilation).</image>

## Diagnosis

### Clinical Assessment

The cardinal symptoms of allergic rhinitis include anterior and posterior rhinorrhea, nasal congestion, paroxysmal sneezing, and nasal pruritus. Associated symptoms frequently include allergic conjunctivitis, which is present as a comorbidity in approximately 70 percent of cases, as well as palatal pruritus and ear pruritus or fullness. Physical examination may reveal several characteristic findings. Allergic shiners, the infraorbital darkening caused by venous congestion, are a common finding. The allergic salute, an upward rubbing gesture of the nose, may produce a visible transverse nasal crease over the lower third of the nose with repeated use. Dennie-Morgan lines, prominent infraorbital folds, provide additional supportive evidence. On anterior rhinoscopy, the nasal turbinates typically appear pale, boggy, and bluish-gray, in contrast to the erythematous mucosa seen in infectious rhinitis. Examination of the posterior pharynx may reveal cobblestoning, a pattern of lymphoid hyperplasia resulting from chronic postnasal drip.

### Allergy Testing

Skin prick testing remains the gold standard for confirming IgE-mediated sensitization. A positive result is defined as a wheal at least 3 mm greater than the negative saline control, read at 15 to 20 minutes. Skin prick testing offers sensitivity of approximately 85 to 90 percent, though patients must discontinue H1 antihistamines for 3 to 7 days before testing to avoid false-negative results. Notably, several medication classes do not interfere with skin testing and need not be held, including leukotriene receptor antagonists, intranasal corticosteroids, decongestants, and short courses of oral corticosteroids.

Serum-specific IgE measurement via ImmunoCAP provides a quantitative alternative when skin prick testing is not feasible, such as in patients with extensive dermatitis, dermatographism, or inability to discontinue antihistamines. Results are not affected by concurrent antihistamine use. However, serum-specific IgE is a quantitative assay that does not measure functional IgE activity, meaning a positive result indicates sensitization but not necessarily clinical relevance.

Component-resolved diagnostics (CRD) represents an advance in molecular allergy diagnosis, identifying IgE directed against individual allergen protein components rather than crude extracts. This approach is particularly valuable for distinguishing genuine sensitization from clinically insignificant cross-reactivity, as exemplified by differentiating true peanut allergy (sensitization to Ara h 2) from cross-reactive carbohydrate determinant positivity. Total serum IgE has poor diagnostic utility for allergic rhinitis, as it does not correlate reliably with specific allergen sensitization. Nasal cytology, when performed, reveals eosinophil predominance in allergic rhinitis, with greater than 5 percent eosinophils on nasal smear considered suggestive.

## Differential Diagnosis

| Condition | Key Distinguishing Features | Allergy Testing | Nasal Cytology |
|-----------|-----------------------------|-----------------|----------------|
| Allergic rhinitis | Pale/boggy turbinates, sneezing, pruritus, conjunctivitis | Positive SPT/sIgE | Eosinophils |
| Non-allergic rhinitis (vasomotor) | Nasal congestion predominant, no itch | Negative | Non-eosinophilic |
| NARES | Eosinophilic cytology, no IgE sensitization | Negative | Eosinophils |
| Local allergic rhinitis | Positive nasal challenge, local IgE in secretions | Negative SPT/sIgE | Eosinophils |
| Rhinitis medicamentosa | History of topical decongestant overuse >3-5 days | Negative | Variable |
| Infectious rhinitis | Erythematous mucosa, purulent discharge | Negative | Neutrophils |

The differential diagnosis of chronic rhinitis is broad and must be carefully considered. Non-allergic rhinitis encompasses several subtypes, including vasomotor or idiopathic rhinitis, gustatory rhinitis, drug-induced rhinitis (from rhinitis medicamentosa due to topical decongestant overuse, ACE inhibitor-related rhinitis, or hormonal contraceptive-associated rhinitis), and hormonal rhinitis (as seen in pregnancy or hypothyroidism). Non-allergic rhinitis with eosinophilia syndrome (NARES) presents a diagnostic challenge, as patients demonstrate eosinophilic nasal cytology without evidence of IgE sensitization on allergy testing. Infectious causes include viral rhinitis (the common cold) and bacterial sinusitis. Structural abnormalities such as nasal septal deviation, turbinate hypertrophy, and nasal polyps must be excluded. A particularly important entity is local allergic rhinitis (LAR), in which patients demonstrate a positive nasal allergen challenge despite negative skin prick testing and undetectable serum-specific IgE, indicating local IgE production confined to the nasal mucosa without systemic sensitization.

## Pharmacotherapy

| Drug Class | Sneezing | Rhinorrhea | Congestion | Pruritus | Ocular Symptoms | Onset |
|-----------|----------|------------|------------|----------|-----------------|-------|
| Intranasal corticosteroids | +++ | +++ | +++ | +++ | ++ | 1-2 weeks (full effect) |
| Oral 2nd-gen antihistamines | ++ | ++ | +/- | +++ | ++ | 1-2 hours |
| Intranasal antihistamines | ++ | ++ | ++ | ++ | + | 15-30 minutes |
| INCS + intranasal antihistamine | +++ | +++ | +++ | +++ | ++ | Hours |
| Leukotriene receptor antagonists | + | + | + | + | + | Days |
| Intranasal ipratropium | - | +++ | - | - | - | 15-30 minutes |
| Intranasal cromolyn | + | + | + | + | - | Days-weeks |

### Intranasal Corticosteroids (INCS) - First-Line

Intranasal corticosteroids represent the most effective single-agent therapy for allergic rhinitis and are recommended as first-line treatment for moderate-severe or persistent disease. They are uniquely effective among pharmacologic options in addressing all cardinal symptoms, including nasal congestion. Available agents include fluticasone propionate, mometasone furoate, fluticasone furoate, budesonide, triamcinolone acetonide, and ciclesonide. These agents suppress multiple inflammatory pathways simultaneously, reducing tissue eosinophils, mast cell numbers, Th2 cytokine expression, and mediator release. While some symptomatic benefit may be appreciated within hours of the first dose, full therapeutic effect typically requires 1 to 2 weeks of regular, consistent use. Systemic absorption is minimal with currently available formulations, with bioavailability less than 2 percent for fluticasone propionate and less than 0.1 percent for mometasone, making long-term use safe in both adults and children. Regular daily use is more effective than as-needed dosing, though the latter may be acceptable for mild intermittent disease. The most common adverse effect is epistaxis, occurring in approximately 10 percent of users, and nasal dryness. Patients should be instructed to direct the spray laterally toward the lateral nasal wall, aiming away from the nasal septum, to minimize the risk of septal irritation and epistaxis.

### Oral and Intranasal Antihistamines

Second-generation oral H1 antihistamines, including cetirizine (10 mg), levocetirizine (5 mg), loratadine (10 mg), desloratadine (5 mg), and fexofenadine (180 mg), are effective for sneezing, rhinorrhea, nasal pruritus, and ocular symptoms but are notably less effective for nasal congestion. Among the second-generation agents, cetirizine is the most likely to cause mild sedation, affecting approximately 10 to 15 percent of users. These agents have an onset of action of 1 to 2 hours and provide efficacy lasting 12 to 24 hours.

Intranasal antihistamines, including azelastine (0.1 to 0.15 percent) and olopatadine (0.6 percent), offer a faster onset of action (15 to 30 minutes) compared with oral formulations and, unlike oral antihistamines, demonstrate efficacy against nasal congestion. Azelastine may cause a bitter taste, and both agents have some potential for sedation. The combination of an intranasal corticosteroid with an intranasal antihistamine, commercially available as Dymista (fluticasone propionate plus azelastine), has been demonstrated in the MPASS and COMPASS studies to be superior to either component used alone, representing the preferred step-up therapy for patients with inadequate response to intranasal corticosteroids as monotherapy.

### Leukotriene Receptor Antagonists

Montelukast (10 mg daily) provides modest efficacy in allergic rhinitis but is inferior to intranasal corticosteroids. In 2020, the FDA issued a black box warning regarding neuropsychiatric adverse events associated with montelukast, including suicidal ideation, depression, and aggression. As a result, its use should be reserved for patients who cannot tolerate or who prefer an alternative to intranasal corticosteroids, and clinicians must discuss these risks with patients. Montelukast may offer the greatest benefit when allergic rhinitis coexists with asthma, given the shared role of leukotrienes in both conditions.

### Other Agents

Oral decongestants such as pseudoephedrine (30 to 60 mg every 4 to 6 hours) provide symptomatic relief of congestion but should be avoided in patients with uncontrolled hypertension and limited to fewer than 7 days of use. Intranasal decongestants, such as oxymetazoline, should be restricted to 3 to 5 days of use to prevent rhinitis medicamentosa, a syndrome of rebound nasal congestion that develops with prolonged topical decongestant use. Intranasal ipratropium bromide (0.03 percent nasal spray) is an anticholinergic agent specifically effective for watery rhinorrhea but without benefit for congestion, sneezing, or pruritus. Intranasal cromolyn, a mast cell stabilizer, is safe but less effective than other agents and requires dosing 4 to 6 times daily, limiting its practical utility. Intranasal saline irrigation, whether isotonic or hypertonic, serves as a valuable adjunctive measure, reducing total symptom scores by approximately 25 percent through mechanical clearance of allergens and mucus from the nasal cavity.

<image>A treatment algorithm flowchart for allergic rhinitis based on ARIA guidelines. Starting point: "Confirmed allergic rhinitis." First branch by severity: Mild intermittent (oral or intranasal antihistamine PRN), Moderate-severe or persistent (intranasal corticosteroid as first-line). Failure of INCS alone: add intranasal antihistamine (combination therapy). Persistent symptoms despite combination: consider allergen immunotherapy (SCIT or SLIT). Special situations boxes: eye symptoms present (add ocular antihistamine or oral antihistamine), predominant congestion (add short-course decongestant), coexisting asthma (consider LTRA and evaluate asthma management). Side panel listing non-pharmacologic measures: allergen avoidance, nasal saline irrigation, HEPA filters, dust mite encasings.</image>

## Environmental Control and Allergen Avoidance

Environmental control measures form an important component of comprehensive allergic rhinitis management, though their effectiveness as isolated interventions is often modest. For dust mite allergy, encasing the mattress, pillow, and box spring in allergen-impermeable covers represents the single environmental measure with the most supporting evidence. Additional measures include washing bedding weekly in hot water at temperatures exceeding 130 degrees Fahrenheit (54 degrees Celsius), maintaining indoor humidity below 50 percent, and removing carpeting from bedrooms. For pet allergens, avoidance remains the most effective strategy, though it is often impractical. The major cat allergen Fel d 1 is particularly persistent in the environment, remaining airborne for hours due to its small particle size, and can persist in a home for months after cat removal. HEPA air filtration and weekly bathing of cats provide modest but limited benefit. Mold control centers on eliminating moisture sources by repairing water leaks, maintaining humidity below 50 percent, removing visible mold growth, and avoiding the use of humidifiers. Cockroach allergen reduction requires integrated pest management strategies, including boric acid bait application, though removal of the existing allergen reservoir may take months to achieve meaningful reduction. For pollen exposure, patients should keep windows closed during periods of high pollen counts, shower and change clothes after outdoor activities, and use nasal saline rinses to clear deposited pollen from the nasal mucosa.

## Complications

Allergic rhinitis predisposes to several complications that warrant recognition and management. Mucosal edema from chronic allergic inflammation can obstruct the sinus ostia, predisposing to acute and chronic sinusitis and increasing the risk of secondary bacterial infection. Eustachian tube dysfunction resulting from nasal mucosal inflammation may lead to otitis media with effusion, particularly in children. Chronic nasal congestion contributes to mouth breathing and may exacerbate obstructive sleep apnea by increasing upper airway resistance. The relationship between allergic rhinitis and asthma is bidirectional: untreated allergic rhinitis is associated with increased frequency and severity of asthma exacerbations, while effective treatment of rhinitis has been shown to improve asthma outcomes.

Oral allergy syndrome, more precisely termed pollen-food allergy syndrome, occurs through IgE cross-reactivity between pollen proteins and structurally homologous proteins in plant-derived foods. The classic example involves birch pollen sensitization cross-reacting with apple, hazelnut, and celery through Bet v 1 homologous PR-10 proteins. Ragweed pollen cross-reacts with melon and banana, while grass pollen cross-reacts with tomato and peach. Symptoms are typically confined to the oropharynx, producing pruritus, tingling, and mild edema of the lips, tongue, and palate upon ingestion of the raw food. Because PR-10 proteins are heat-labile, cooked forms of the food are generally tolerated. However, sensitization to lipid transfer proteins (LTPs), which are heat-stable and found more commonly in Mediterranean populations, carries a risk of systemic allergic reactions including anaphylaxis.

<image>An infographic-style illustration of pollen-food allergy syndrome (oral allergy syndrome). Central image shows a pollen grain and its corresponding cross-reactive foods arranged in a circular pattern. Four main clusters: (1) Birch pollen connected to apple, cherry, peach, hazelnut, carrot, celery, soy (labeled "PR-10/Bet v 1 homologs - heat labile"), (2) Ragweed pollen connected to banana, melon, watermelon, zucchini, cucumber, (3) Grass pollen connected to tomato, melon, orange, (4) Mugwort pollen connected to celery, carrot, spices, mustard ("celery-mugwort-spice syndrome"). Include a legend noting heat-labile vs heat-stable (LTP) proteins. Small inset showing a patient with lip and oropharyngeal edema after eating raw apple.</image>

## Key Clinical Pearls
- Intranasal corticosteroids are first-line for moderate-severe AR; instruct patients to spray laterally toward the lateral nasal wall (away from septum) to minimize epistaxis
- Combination intranasal steroid + intranasal antihistamine (e.g., Dymista) is superior to either component alone for moderate-severe disease
- Montelukast carries an FDA black box warning for neuropsychiatric events; use should be reserved for specific clinical scenarios
- Medications that do NOT need to be held before allergy skin testing: nasal steroids, oral steroids (<2 weeks), montelukast, decongestants
- Local allergic rhinitis is characterized by negative SPT/serum IgE with positive nasal allergen challenge and local IgE in nasal secretions
- Rhinitis medicamentosa occurs with topical decongestant use >3-5 days; treat with intranasal steroids and decongestant taper
- Oral allergy syndrome from PR-10 proteins (Bet v 1 homologs) is heat-labile; cooked forms of the food are typically tolerated

## References
1. Bousquet J, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update. *Allergy*. 2008;63(Suppl 86):8-160.
2. Dykewicz MS, et al. Treatment of seasonal allergic rhinitis: an evidence-based focused 2017 guideline update. *Ann Allergy Asthma Immunol*. 2017;119(6):489-511.
3. Carr WW, et al. A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. *J Allergy Clin Immunol*. 2012;129(5):1282-1289.
4. Rondon C, et al. Local allergic rhinitis: concept, pathophysiology, and management. *J Allergy Clin Immunol*. 2012;129(6):1460-1467.
5. Seidman MD, et al. Clinical practice guideline: allergic rhinitis. *Otolaryngol Head Neck Surg*. 2015;152(1 Suppl):S1-S43.